BioCryst (BCRX) Trades at Just 11x Forward Earnings. Is the Market Pricing In Trouble?
BioCryst Pharmaceuticals (BCRX) reported Q2 2026 revenue of $218.3M, up 34% YoY, with Orladeyo contributing $158.2M. The company faces potential competition from Pharvaris' HAE treatment. Analysts have mixed views on BCRX's future, with RBC downgrading and Wedbush maintaining an Outperform rating. BCRX trades at 10.83x forward earnings, below the sector median.
How this was made
The 30-second read
Why it matters
The key trade question is whether new oral-prevention competition accelerates Orladeyo revenue deceleration, outweighing pediatric label expansion and the company’s forward revenue guidance.
Market read
Investors may reassess Orladeyo’s long-term revenue tail and valuation multiple as new oral-prevention clinical data emerges.
What to watch
The article notes no direct head-to-head vs Orladeyo; differences in endpoints, patient selection, and payer dynamics could reduce real-world substitution risk.
Background
BioCryst’s Orladeyo is the main recurring revenue driver, while navenibart is in pivotal development and Pharvaris is advancing an oral preventive therapy for HAE.
Ticker impact
BioCryst is assessed on Orladeyo’s durability as Pharvaris’ Phase 3 deucrictibant XR results introduce a potential oral HAE competitor.
Likely downside bias as investors reprice Orladeyo’s long-term revenue tail amid new oral-prevention competition.
The article links Pharvaris’ positive Phase 3 data to uncertainty around Orladeyo growth, while also citing RBC’s downgrade and a lower Orladeyo revenue tail scenario.
Market effects
Highlights how new late-stage clinical data in hereditary angioedema can reset competitive expectations for established biotech revenue franchises.
No clear regional market catalyst beyond US biotech sentiment.
Competition in an international HAE market can affect global pricing and uptake expectations for oral preventives.
Counterpoint
Orladeyo’s pediatric expansion and ongoing navenibart development could extend the franchise longer than the competitive threat implies, limiting multiple compression.
Key entities
- companyBioCryst Pharmaceuticals, Inc.
NASDAQ-listed biotech whose Orladeyo revenue durability is evaluated amid new oral HAE preventive competition.
- companyPharvaris
Late-stage HAE developer whose Phase 3 deucrictibant XR results are used as a competitive read-through for Orladeyo.
- productOrladeyo
BioCryst’s approved oral preventive therapy for hereditary angioedema.
- productdeucrictibant XR
Pharvaris investigational oral preventive therapy with reported Phase 3 positive results.
- productnavenibart
BioCryst investigational therapy with pivotal ALPHA-ORBIT enrollment completed and top-line results expected in 3Q 2027.
